Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study
Internal Medicine Journal · 2025
DOI: 10.1111/imj.16576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Cassandra White und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Neoplasms, Antineoplastic Agents. Die Arbeit nennt 37 Literaturangaben. Gefördert von: University of Newcastle Australia.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Implementing pharmacogenomic‐guided management in cancer patients equitably and effectively in a large population presents challenges. DPYD genotyping determines clinically significant variants of patients at increased risk of developing grade3–5 fluoropyrimidine (FP) toxicity. FP chemotherapies are prescribed for ~16,000 Australians with a 10%–40% grade3–4 toxicity incidence and 1% mortality. Variant carriers can have FP dosing adjusted to improve treatment tolerance without compromising anticancer effect. This strategy has not been formally adopted within Australia, despite widespread international standardisation.
Aim
This pilot study determined genotyping turnaround‐times (TAT) for 4 DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T and c.1236G>A/Haplotype B3) in Australian patients. Secondary objectives were identification of FP toxicities of DPYD variant carriers, and analysis of healthcare stakeholder perspectives, including enablers/barriers to implementation.
Methods
Genotyping was determined by Real‐Time Polymerase Chain Reaction. Qualitative data were determined through semi‐structured questionnaire.
Results
104 patients recruited over 24 months had a mean TAT of 7.2 days, 5.2 business days (range 1–30). Grade3–4 toxicity occurred in 9/16 DPYD variant carriers, including 2 ICU admissions and 1 death. Themes from 30 questionnaire respondents suggest that clinical environment and resources were fundamental barriers, and motivation to improve patient care was the predominant enabler of change.
Conclusion
DPYD genotyping is feasible for improving precision‐oncology for patients requiring FP chemotherapies. A TAT of 7 days is acceptable by both stakeholder respondents and national oncology clinician groups. This pilot study, although small, informs a large national project evaluating prospective DPYD genotyping and its impact on FP tolerability, patient safety and cost‐effectiveness in Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
- Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
- Department of Molecular Genetics, Pathology North John Hunter Hospital, Newcastle, New South Wales, Australia.
- College of Health, Medicine and Wellbeing, School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
ORCID-Profile: Cassandra White, Stephen Ackland
Förderung
- University of Newcastle Australia
Zitieren
APA
White, C., Paul, C., Liet, E., Kalpage, D., Mossman, D., Ziolkowski, A., Ackland, S., & Scott, R. J. (2025). Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study. Internal Medicine Journal. https://doi.org/10.1111/imj.16576
Vancouver
White C, Paul C, Liet E, Kalpage D, Mossman D, Ziolkowski A, et al. Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study. Internal Medicine Journal. 2025. doi:10.1111/imj.16576
BibTeX
@article{White2025,
author = {White, Cassandra and Paul, Christine and Liet, Esther and Kalpage, Dilshan and Mossman, David and Ziolkowski, Andrew and Ackland, Stephen and Scott, Rodney J},
title = {Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16576}
}
EUVIMED